Increases in metabolism of valproate and excretion of 6β-hydroxycortisol in patients with traumatic brain injury

被引:8
作者
Anderson, GD
Awan, AB
Adams, CA
Temkin, NR
Winn, HR
机构
[1] Univ Washington, Dept Pharm, Sch Pharm, Seattle, WA 98195 USA
[2] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98195 USA
[3] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA
关键词
valproate; 6-beta-hydroxycortisol; cortisol; brain injury; metabolism;
D O I
10.1046/j.1365-2125.1998.00652.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The objectives of this study were to determine the effect of brain trauma on the multiple pathways of metabolism of valproate and to evaluate the use of the urinary 6 beta-hydroxycortisol to cortisol ratio in predicting changes in hepatic metabolism induced by brain injury. Methods Fourteen patients with severe head injuries received a 15 mg kg(-1) loading dose and a maintenance dose of valproate to maintain therapeutic plasma concentrations. A minimum of one steady state trough blood sample and one dosage interval urine were collected during days 3-6 and during days 7-14 post-injury. Total and unbound valproate plasma concentrations were determined by gas chromatography-flame ionization detection (GC-FID) with and without ultrafiltration. Urinary valproate metabolites were measured by gas chromatography/mass spectrometry (GC-MS) (n=10). Urinary 6 beta-hydroxycortisol and cortisol concentrations were determined by high performance liquid chromatography (h.p.l.c.) (n=14). Total intrinsic clearance (CLint) for valproate and individual formation clearances (CLf) to its major metabolites were calculated. Data obtained during baseline (days 3-6) were averaged for each patient and were compared with averaged data obtained from days 7 to 14 using a paired t-test. Results Statistically significant increases in the CLint, CLf of VPA glucuronide, 2-ene-VPA, and 4-OH-VPA pathways and the 6 beta-hydroxycortisol to cortisol ratio were found. The percent change in the 6 beta-hydroxycortisol to cortisol ratio correlated significantly with the changes in the CLint of valproate. Conclusions Brain trauma results in induction of multiple pathways of valproate metabolism and increases in the 6 beta-hydroxycortisol to cortisol ratio, suggesting a non-specific enzyme induction in response to head injury.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 27 条
[1]   DECREASED PLASMA-PROTEIN BINDING OF VALPROATE IN PATIENTS WITH ACUTE HEAD TRAUMA [J].
ANDERSON, GD ;
GIDAL, BE ;
HENDRYX, RJ ;
AWAN, AB ;
TEMKIN, NR ;
WILENSKY, AJ ;
WINN, HR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :559-562
[2]   Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia [J].
Anderson, GD ;
Pak, C ;
Doane, KW ;
Griffy, KG ;
Temkin, NR ;
Wilensky, AJ ;
Winn, HR .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (03) :279-284
[3]  
Baillie Thomas A., 1995, P589
[4]  
BIENVENU T, 1991, INT J CLIN PHARM TH, V29, P441
[5]   PHENYTOIN PHARMACOKINETICS IN CRITICALLY ILL TRAUMA PATIENTS [J].
BOUCHER, BA ;
RODMAN, JH ;
JARESKO, GS ;
RASMUSSEN, SN ;
WATRIDGE, CB ;
FABIAN, TC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (06) :675-683
[6]   EFFECT OF NEUROTRAUMA ON HEPATIC DRUG CLEARANCE [J].
BOUCHER, BA ;
KUHL, DA ;
FABIAN, TC ;
ROBERTSON, JT .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) :487-497
[7]   THE URINARY 6-BETA-HYDROXYCORTISOL EXCRETION IN MAN ON INDUCERS AND INHIBITORS OF THE HEPATIC MIXED-FUNCTION OXIDASE [J].
DESAGER, JP ;
DUMONT, E ;
HARVENGT, C .
PHARMACOLOGY & THERAPEUTICS, 1987, 33 (01) :197-199
[8]   THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION [J].
GED, C ;
ROUILLON, JM ;
PICHARD, L ;
COMBALBERT, J ;
BRESSOT, N ;
BORIES, P ;
MICHEL, H ;
BEAUNE, P ;
MAUREL, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) :373-387
[9]   PHENYTOIN PROTEIN-BINDING IN PEDIATRIC-PATIENTS WITH ACUTE TRAUMATIC INJURY [J].
GRIEBEL, ML ;
KEARNS, GL ;
FISER, DH ;
WOODY, RC ;
TURLEY, CP .
CRITICAL CARE MEDICINE, 1990, 18 (04) :385-391
[10]  
GRIFFETH LK, 1983, DRUG METAB DISPOS, V11, P517